Posts

Polymyalgia Rheumatica: From Diagnosis to Long-Term Disease Control – Current Recommendations and Unmet Needs Objectives: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease affecting adults aged 50 years and older, characterized by bilateral pain and stiffness in the shoulder and pelvic girdles and a substantial impact on physical function and quality of life. Despite its relatively high prevalence, PMR remains a challenging condition due to heterogeneous clinical presentation, frequent diagnostic uncertainty, and a chronic or relapsing disease course in

UP Standard Of Care in AS with Upadacitinib ObjectivesThis symposium will take you through understanding of axSpA spectrum & patient burden, comprehensive review on diagnosis & treatment guidelines, and factors to be considered in your routine clinic sessions. Upadacitinib can provide clinical benefit for patients encompassing nr-axSpA & r-axSpA, differential pain control as well as EMM management, and also long- term treatment goal of slowing down radiographic progression. Please attend the symposium and explore how to improve standard of care

Navigating Heterogeneity and Harnessing Innovative Therapies in SLE Review the complex immunopathogenesis and clinical heterogeneity of SLE. Identify current gaps in biomarker-guided treatment and clinical monitoring. Evaluate the rationale and clinical evidence for emerging targeted therapies. Agenda – Friday 30 October Chairperson: Prof Yoon-Kyoung Sung, Republic of Korea 1020 – 1030 Welcome and opening Prof Yoon-Kyoung Sung, Republic of Korea 1030 – 1045 Deciphering SLE Heterogeneity: From Pathogenesis to Prognosis Prof Sandra Navarra, Philippines 1045 – 1100 The Precision Gap:

Reframing Long-Term SLE Care in Asia: Reducing Steroid Burden and Advancing Organ Protection Objectives:This scientific symposium will address contemporary management challenges in SLE in Asia, with emphasis on minimizing cumulative glucocorticoid exposure and preventing organ damage. Faculty will review disease burden and the clinical consequences of prolonged glucocorticoid use, then examine mechanism‑based treatment strategies with a focus on B‑cell biology and evidence supporting BLyS inhibition and other B‑cell–directed approaches. A dedicated segment will discuss lupus nephritis, outlining the rationale and

Phase III Clinical Trial Results of CT-P47(AVTOZMA) and Real-World Case Review Objectives: Information coming soon.  Agenda – Friday 30 October TBC Chairperson: Prof Eun Young Lee, Republic of Korea TBC Speaker: Prof Bora Nam, Republic of Korea

Redefining Autoimmune Interstitial Lung Disease Journey: From Early Risk Recognition to Long-term Care Objectives:Autoimmune diseases are a major cause of interstitial lung disease (ILD), with pulmonary fibrosis driving morbidity and mortality. This session will examine risk identification, key clinical and radiological signals of progression, and translation of guidelines into personalised care, concluding with emerging concepts and innovations shaping the future management of autoimmune ILD. Agenda – Saturday 31 October Chairperson: Prof Shin-Seok Lee, Republic of Korea 1250-1255 Opening and welcome

Optimizing RA Outcomes with Upadacitinib: From Treat-to-Target to Real-World Decision-Making Objectives:The principle of treat-to-target has proved successful in diverse disease, and the symposium will deep dive into treat-to-target approach in RA and its value to achieve early remission. Clinical evidence from research outcomes & real-world experience will further support treatment outcome optimization. Agenda – Saturday 31 October Chairperson: Prof Seung-Ki Kwok, Republic of Korea 1025-1030 Opening remarks Prof Seung-Ki Kwok, Republic of Korea 1030-1110 1. The value of Treat-to-target and

Transforming the Trajectory: Early Inflammation Control as a Path to Lasting Change in Spondyloarthritis Objectives: Persistent inflammation in spondyloarthritis (SpA) drives long-term functional impairment and structural damage. This symposium will review how early intervention and effective therapy may influence disease progression, patient-reported outcomes and quality of life. Recent clinical trial data for bimekizumab will be discussed in the context of deep, rapid control of inflammation as well as sustained disease control and long-term management strategies. Agenda – Saturday 31 October